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Abstract
Background: The dopamine dysregulation hypothesis of schizophrenia posits that positive,
negative and cognitive symptoms correlate with cortical/subcortical imbalances in dopaminergic
transmission. A functional polymorphism (Val158Met) in the catechol-O-methyltransferase (COMT)
gene is implicated in the pathophysiology of schizophrenia by its effect on prefrontal dopamine
transmission, and its unique impact on prefrontal cognitive and behavioral phenotypes. Cognitive
impairments and negative symptoms in schizophrenia have been hypothesized to be associated with
hypodopaminergic states. Schizophrenia patients with the deficit syndrome are characterized by
primary enduring negative symptoms, impairment on neurocognitive tasks sensitive to frontal and
parietal cortical functioning, and poorer functional outcome compared to non-deficit patients.
Methods: Eighty-six schizophrenia cases that met DSM-IV criteria for schizophrenia were
recruited. Additional categorization into deficit and nondeficit syndrome was performed using the
Schedule for the Deficit Syndrome (SDS). A healthy comparison group (n = 50) matched to cases
on age and ethnicity was recruited. Allele and genotype frequencies of the Val158Met polymorphism
were compared among healthy controls, and schizophrenia cases with the deficit (n = 21), and
nondeficit syndrome (n = 65).
Results: There was a significant difference in Val/Val genotype frequencies between schizophrenia
cases (combined deficit/nondeficit) and healthy controls (p = 0.004). No significant differences in
allele or genotype frequencies were observed between deficit and nondeficit cases.
Conclusion: Results from this preliminary analysis failed to show an effect of COMT gene on
deficit schizophrenia.
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Schizophrenia is a complex phenotype with a multifacto-
rial etiology. Reducing heterogeneity by identifying alter-
native phenotypes or valid subtypes that reflect specific
neurobiological processes in the pathophysiology of the
disorder is critical to uncovering susceptibility genes [1-3].
The concept of the deficit syndrome subtype of schizo-
phrenia arose in an attempt to reduce clinical heterogene-
ity [4-6]. The deficit syndrome is characterized by primary
(idiopathic) and enduring negative symptoms that persist
through epochs of clinical stability and decompensation.
By definition, idiopathic negative symptoms are not
attributable to paranoid or psychotic withdrawal, depres-
sion, anxiety, or medication side effects. Schizophrenia
patients who do not meet the deficit syndrome criteria are
classified as nondeficit. Compelling evidence supports the
construct validity of the deficit/nondeficit subgrouping on
clinical features and prognosis, risk factors, neurocogni-
tive and biological correlates, and pharmacological
response profiles, and that dysfunction in the neural cir-
cuit that includes the dorsolateral prefrontal cortex
(DLPFC) form the neuropathological basis for the deficit
syndrome [6,7].
The reformulated dopamine hypothesis of schizophrenia
describes interdependent prefrontal hypodopaminergia
(associated with negative and cognitive symptoms) and
subcortical hyperdopaminergia (associated with positive
symptoms) [8]. The COMT gene is implicated in the
pathophysiology of schizophrenia by its effect on prefron-
tal dopamine. A functional single nucleotide polymor-
phism (SNP) (Val158Met) of COMT gene results in two
common variants, Valine (Val) and methionine (Met),
which correspond to low and high synaptic dopamine
respectively [9]. Associations between the Val158Met SNP
and cognitive phenotypes have been described in healthy
and schizophrenia individuals [10-12].
The COMT gene maps to chromosome 22q11.2, a region
implicated in schizophrenia linkage studies, and in velo-
cardiofacial syndrome (VCFS), which is characterized by
psychosis and cognitive deficits [13,14]. COMT is thought
to exert a distinctive effect on prefrontal dopamine-related
information processing because it is primarily expressed
in prefrontal cortical neurons [15,16], and is the principal
enzyme in the degradation of dopamine (up to 60%) in
the DLPFC; a role supported by data from animal studies
[17]. Furthermore, the dopamine transporter, another key
dopamine metabolizing enzyme in the brain is less
expressed in the prefrontal cortex [18]. Deficit schizophre-
nia is characterized by impairments in tasks sensitive to
frontal and parietal cortical functioning [19]. We have
previously demonstrated association between COMT 158
Val allele and schizophrenia in a biracial cohort of
patients from the Baltimore Metropolitan area [20]. In the
current report, we have extended our previous study to
evaluate the association between the variant Val allele and
deficit/nondeficit schizophrenia. We hypothesized that
the Val allele would occur more frequently in deficit than
in nondeficit schizophrenia.
Materials and methods
Eighty-six unrelated schizophrenia individuals were
recruited from the Maryland Psychiatric Research Center
(MPRC). Healthy controls (n = 50) were recruited through
newspaper advertisements targeting the same geographic
region. All participants gave written informed consent,
which was approved by the University of Maryland Insti-
tutional Review Board. Additional evaluation of the
capacity to sign consent was performed on patients to
assess their understanding of the study [21]. As in our pre-
vious study, there was no COMT genotype or allele asso-
ciation in African-American subjects, so this group was
not included in the current study (n = 80). Patients met
the Structured Clinical Interview for DSM-IV (SCID-IV)
[22] criteria for schizophrenia or schizoaffective disorder.
Additional categorization into deficit (n = 21), and non-
deficit syndrome (n = 65) was performed with the Sched-
ule for the Deficit Syndrome (SDS). For the diagnosis of
deficit schizophrenia, this instrument requires the pres-
ence of two or more idiopathic and enduring negative
symptoms (Kirkpatrick et al, 1989). Inter-rater reliabilities
among the clinical interviewers were above 0.80 (inter-
class correlation). The Structured Interview for DSM-IV
Personality Diagnoses (SIDP) [23], and Family History-
Research Diagnostic Criteria (FH-RDC) [24] were admin-
istered in controls. Healthy controls had no Axis I diag-
noses, or schizophrenia spectrum personality disorders.
Genotyping methods are described elsewhere [20].
Briefly, venous whole blood was collected and DNA iso-
lated by standard means. COMT Val158Met SNP was deter-
mined as a restriction fragment length polymorphism
(RFLP) after PCR amplification according to the method
of Egan et al. (2001).
Fisher's exact test was used to evaluate whether the
observed distribution of COMT Val158Met genotypes was
consistent with that expected under Hardy Weinberg equi-
librium. Nominal logistic regression (with age and sex as
predictor variables) was used to determine the effect of
genotype on disease status under an additive genetic
model (i.e., by assigning values of -1, 0, and 1 to the three
genotype classes). We first evaluated the effect of genotype
on the total schizophrenia endpoint, combining the defi-
cit and nondeficit subtypes. We then evaluated genotype
effects on the deficit only schizophrenia endpoint.Page 2 of 5
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The sample consists of 136 European-American subjects
(21 deficit cases, 65 nondeficit cases, and 50 healthy con-
trols) presented in Table 1. The observed COMT genotype
distributions were consistent with that expected under
Hardy Weinberg equilibrium. Comparisons of COMT
genotype frequencies between cases and controls are pre-
sented in Table 1. COMT genotype was significantly asso-
ciated with schizophrenia (deficit and nondeficit
combined; age- and sex-adjusted Odds Ratio = 3.24, p =
0.004 by genotype test), with Val allele frequencies of 0.68
and 0.43, in cases and controls, respectively. In contrast,
genotype (and allele) frequencies did not differ between
deficit and nondeficit cases (allele frequencies 0.74 and
0.66, respectively; age- and sex-adjusted p = 0.8). Deficit
schizophrenia was observed in one female: COMT genetic
variation has been previously shown to produce sexual
dimorphism in brain dopamine levels; we repeated the
analyses comparing COMT genotype between deficit and
nondeficit subtypes in males only. We again observed that
genotype (and allele) frequencies did not differ between
both groups (allele frequencies 0.72 and 0.58, respec-
tively; p = 0.19). Given the small sample size, we esti-
mated the least detectable difference in allele frequencies
that could have been observed in our sample between def-
icit and nondeficit cases. Given the observed Val allele fre-
quency of 0.66 in nondeficit cases, the frequency in the
deficit group would have had to have been less than 0.42
or greater than 0.87 in order to detect a significant differ-
ence between groups (at alpha = 0.05) with 80% power.
Discussion
In this report we did not observe a significant difference
between deficit and nondeficit schizophrenia subtypes in
either COMT allele or genotype frequencies. Our report
however provides an extension of our earlier finding of
association between COMT158Val allele and schizophre-
nia in a larger sample of European-American subjects with
the addition of deficit schizophrenia individuals. Similar
to our prior report, we failed to find association between
COMT gene and schizophrenia in the African-American
subgroup. This suggests that COMT allele frequencies
might be different in both ethnic groups in this Baltimore
sample. To avoid potential population substratification,
we did not include African-Americans in the current
report. In our previous study based on 61 European-
Americans with schizophrenia, we observed allele fre-
quencies of 0.62 and 0.50 in cases and healthy controls (p
= 0.04). The differences in allele frequencies persisted,
and indeed increased in this study on a modestly
expanded sample (to 0.680 vs. 0.430), which includes 86
European-American schizophrenia cases presented in this
report. Evidence from family-based and case-control stud-
ies generally suggest that COMT Val158Met polymorphism
might be associated with schizophrenia [25] with some
negative reports [26,27].
Table 1: Demographic information and COMT genotype
Schizophrenia Subjects Healthy controls Total
Sex Nondeficit Deficit Total patients
Female N 28 1 29 22 51
Age Mean (SD) 47.08 (8.94) 55 (0.0) 47.36 (8.91) 44.31 (17.59) 46.04 (13.29)
Val-Val 16 1 17 6 23
Val-Met 11 0 11 10 21
Met-Met 1 0 1 6 7
Male N 37 20 57 28 85
Age Mean (SD) 43.80 (10.14) 43.74 (11.12) 43.78 (10.40) 46.89 (17.87) 44.80 (13.30)
Val-Val 14 10 24 3 27
Val-Met 15 9 24 15 39
Met-Met 8 1 9 10 19
Total N 65 21 86 50 136
Age Mean (SD) 45.21 (9.71) 44.28 (11.12) 44.98 (10.01) 45.76 (17.62) 45.27 (13.26)
Val-Val 30 11 41 9 50
Val-Met 26 9 35 25 60
Met-Met 9 1 10 16 26
N = number
SD = standard deviation
Val = Valine variant allele
Met = Methionine variant allele
COMT = catechol-O-methyltransferasePage 3 of 5
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which may have limited detecting associations of only
modest size between COMT gene and deficit/nondeficit
subtypes. The differences are so small that the power
needed to detect a significant difference between both
subtypes would indeed require a large sample. However,
our findings are unlikely due to type II error. Our reported
allele and genotype frequencies were similar between the
deficit and nondeficit schizophrenia subgroups, but con-
siderably higher than the frequencies observed in healthy
controls. In this sample, the patient group is comprised of
a significantly higher proportion of males than the control
group. Furthermore, there are substantially more males in
the deficit group, which is consistent with prior reports on
deficit schizophrenia (Kirkpatrick et al, 2001). Prior stud-
ies have reported a sexual dimorphism in COMT-associ-
ated dopamine levels on several neuropsychiatric
phenotypes in a region-specific manner, particularly in
the frontal cortex [28,29]. Analyses using a regression
model controlled for age and sex effects on our COMT
findings in this Baltimore sample.
Conclusion
The results do not support a differential COMT gene effect
on the deficit/nondeficit subtypes of schizophrenia.
Future studies in larger independent samples investigating
joint interactions with other candidate dopamine system
genes (e.g. dopamine transporter gene [DAT1]) and
COMT gene on schizophrenia endophenotypes are war-
ranted.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
IW, OCS, and RWB collected and analyzed the data for
this study, with assistance from LEH, GKT, BK, and WTC.
BDM and AE assisted with statistical analyses. All authors
contributed intellectually to the design of this study. All
authors read and approved the final manuscript.
Acknowledgements
This work was supported in part by National Institute of Health (MH 45074 
60487 68282 67014 68580), General Clinical Research Center (GCRC), 
and VISN5 MIRREC.
References
1. Adler LE, Freedman R, Ross RG, Olincy A, Waldo MC: Elementary
phenotypes in the neurobiological and genetic study of schiz-
ophrenia.  Biol Psychiatry 1999, 46:8-18.
2. Harrison PJ, Weinberger DR: Schizophrenia genes, gene expres-
sion, and neuropathology: on the matter of their conver-
gence.  Mol Psychiatry 2004.
3. Tsuang MT: Defining alternative phenotypes for genetic stud-
ies: what can we learn from studies of schizophrenia?  Am J
Med Genet 2001, 105:8-10.
4. Carpenter WT Jr., Heinrichs DW, Wagman AM: Deficit and non-
deficit forms of schizophrenia: the concept.  Am J Psychiatry
1988, 145:578-583.
5. Buchanan RW, Carpenter WT: Domains of psychopathology: an
approach to the reduction of heterogeneity in schizophre-
nia.  J Nerv Ment Dis 1994, 182:193-204.
6. Carpenter WT Jr., Arango C, Buchanan RW, Kirkpatrick B: Deficit
psychopathology and a paradigm shift in schizophrenia
research.  Biol Psychiatry 1999, 46:352-360.
7. Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr.: A sepa-
rate disease within the syndrome of schizophrenia.  Arch Gen
Psychiatry 2001, 58:165-171.
8. Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska
BK, Berman KF, Goldberg TE: Prefrontal neurons and the genet-
ics of schizophrenia.  Biol Psychiatry 2001, 50:825-844.
9. Lachman HM, Morrow B, Shprintzen R, Veit S, Parsia SS, Faedda G,
Goldberg R, Kucherlapati R, Papolos DF: Association of codon
108/158 catechol-O-methyltransferase gene polymorphism
with the psychiatric manifestations of velo-cardio-facial syn-
drome.  Am J Med Genet 1996, 67:468-472.
10. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM,
Straub RE, Goldman D, Weinberger DR: Effect of COMT Val108/
158 Met genotype on frontal lobe function and risk for schiz-
ophrenia.  Proc Natl Acad Sci U S A 2001, 98:6917-6922.
11. Goldberg TE, Egan MF, Gscheidle T, Coppola R, Weickert T, Kolach-
ana BS, Goldman D, Weinberger DR: Executive subprocesses in
working memory: relationship to catechol-O-methyltrans-
ferase Val158Met genotype and schizophrenia.  Arch Gen Psy-
chiatry 2003, 60:889-896.
12. Rosa A, Peralta V, Cuesta MJ, Zarzuela A, Serrano F, Martinez-Larrea
A, Fananas L: New evidence of association between COMT
gene and prefrontal neurocognitive function in healthy indi-
viduals from sibling pairs discordant for psychosis.  Am J Psychi-
atry 2004, 161:1110-1112.
13. Murphy KC, Jones LA, Owen MJ: High rates of schizophrenia in
adults with velo-cardio-facial syndrome.  Arch Gen Psychiatry
1999, 56:940-945.
14. Karayiorgou M, Gogos JA: The molecular genetics of the 22q11-
associated schizophrenia.  Brain Res Mol Brain Res 2004,
132:95-104.
15. Kastner A, Anglade P, Bounaix C, Damier P, Javoy-Agid F, Bromet N,
Agid Y, Hirsch EC: Immunohistochemical study of catechol-O-
methyltransferase in the human mesostriatal system.  Neuro-
science 1994, 62:449-457.
16. Matsumoto M, Weickert CS, Beltaifa S, Kolachana B, Chen J, Hyde
TM, Herman MM, Weinberger DR, Kleinman JE: Catechol O-meth-
yltransferase (COMT) mRNA expression in the dorsolateral
prefrontal cortex of patients with schizophrenia.  Neuropsy-
chopharmacology 2003, 28:1521-1530.
17. Tunbridge EM, Bannerman DM, Sharp T, Harrison PJ: Catechol-o-
methyltransferase inhibition improves set-shifting perform-
ance and elevates stimulated dopamine release in the rat
prefrontal cortex.  J Neurosci 2004, 24:5331-5335.
18. Sesack SR, Hawrylak VA, Matus C, Guido MA, Levey AI: Dopamine
axon varicosities in the prelimbic division of the rat prefron-
tal cortex exhibit sparse immunoreactivity for the dopamine
transporter.  J Neurosci 1998, 18:2697-2708.
19. Buchanan RW, Strauss ME, Breier A, Kirkpatrick B, Carpenter WT:
Attentional impairments in deficit and nondeficit forms of
schizophrenia.  Am J Psychiatry 1997, 154:363-370.
20. Wonodi I, C. S, Mitchell BD, Buchanan R, Thaker G: Association
between Val 108/158 Met polymorphisms of the COMT gene
and schizophrenia.  Am J Med Genet 2003, 120B:47-50.
21. Carpenter WT Jr., Gold JM, Lahti AC, Queern CA, Conley RR, Bar-
tko JJ, Kovnick J, Appelbaum PS: Decisional capacity for informed
consent in schizophrenia research.  Arch Gen Psychiatry 2000,
57:533-538.
22. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Inter-
view for DSM-IV Axis I Disorders Arlington, American Psychiatric Pub-
lishing, Inc; 1997. 
23. Pfohl B, Blum N, Zimmerman M: Structured Interview for DSM-IV Per-
sonality 1997.
24. Andreasen NC, Endicott J, Spitzer RL, Winokur G: The family his-
tory method using diagnostic criteria. Reliability and validity.
Arch Gen Psychiatry 1977, 34:1229-1235.Page 4 of 5
(page number not for citation purposes)
Behavioral and Brain Functions 2006, 2:42 http://www.behavioralandbrainfunctions.com/content/2/1/42Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
25. Glatt SJ, Faraone SV, Tsuang MT: Association between a func-
tional catechol O-methyltransferase gene polymorphism
and schizophrenia: meta-analysis of case-control and family-
based studies.  Am J Psychiatry 2003, 160:469-476.
26. Williams HJ, Glaser B, Williams NM, Norton N, Zammit S, Macgregor
S, Kirov GK, Owen MJ, O'Donovan MC: No Association Between
Schizophrenia and Polymorphisms in COMT in Two Large
Samples.  Am J Psychiatry 2005, 162:1736-1738.
27. Fan JB, Zhang CS, Gu NF, Li XW, Sun WW, Wang HY, Feng GY, St
Clair D, He L: Catechol-O-methyltransferase gene Val/Met
functional polymorphism and risk of schizophrenia: a large-
scale association study plus meta-analysis.  Biol Psychiatry 2005,
57:139-144.
28. Dauvilliers Y, Neidhart E, Lecendreux M, Billiard M, Tafti M: MAO-A
and COMT polymorphisms and gene effects in narcolepsy.
Mol Psychiatry 2001, 6:367-372.
29. Qian Q, Wang Y, Zhou R, Li J, Wang B, Glatt S, Faraone SV: Family-
based and case-control association studies of catechol-O-
methyltransferase in attention deficit hyperactivity disorder
suggest genetic sexual dimorphism.  Am J Med Genet B Neuropsy-
chiatr Genet 2003, 118:103-109.Page 5 of 5
(page number not for citation purposes)
